Amneal Pharmaceuticals, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports the results of the 2024 Annual Meeting of Stockholders held by Amneal Pharmaceuticals, Inc. on May 2, 2024. The filing details the voting outcomes for director elections, executive compensation, and the ratification of the independent auditor.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes
No material financial changes or operational updates are disclosed in this filing. The document serves as a record of shareholder votes.
Outlook, Risks, and Voting Results
All three proposals submitted to the stockholders were approved:
- Proposal 1 (Director Elections): All 11 director nominees were elected. Notable voting statistics include:
- Emily Peterson Alva: 253,927,467 For; 1,736,375 Against.
- Paul Meister: 238,720,752 For; 16,941,409 Against (highest "Against" vote count).
- Gautam Patel: 251,712,874 For; 3,732,183 Against.
- Shlomo Yanai: 254,374,881 For; 1,067,043 Against.
- Proposal 2 (Executive Compensation): Approved on a non-binding advisory basis with 254,365,134 votes For and 1,199,935 votes Against.
- Proposal 3 (Auditor Ratification): Ernst & Young LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2024, with 279,106,284 votes For and 624,760 votes Against.
Key Facts for Investor Verification
- Verify the total number of shares entitled to vote versus the actual votes cast to assess shareholder engagement levels.
- Review the specific reasons for the higher "Against" votes for directors Paul Meister and Gautam Patel compared to other nominees.
- Confirm the tenure of the newly elected directors, which extends until the 2025 Annual Meeting.
- Check subsequent filings for the company's Q1 2024 financial results, as this 8-K contains no financial data.